# To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis

> **NCT05495568** · PHASE3 · COMPLETED · sponsor: **Celltrion** · enrollment: 367 (actual)

## Conditions studied

- Moderate to Severe Chronic Plaque Psoriasis

## Interventions

- **BIOLOGICAL:** CT-P17
- **BIOLOGICAL:** EU-approved Humira

## Key facts

- **NCT ID:** NCT05495568
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-07
- **Primary completion:** 2023-08-14
- **Final completion:** 2024-02-05
- **Target enrollment:** 367 (ACTUAL)
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05495568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05495568, "To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05495568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*